David Chang | BiotechTV

top of page

ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate

CEO David Chang describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on...

Company News

Jun 2

Making the case for allo durability at #ASCO23 with Allogene’s CEO

Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.

Company News

Jun 4, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate

Making the case for allo durability at #ASCO23 with Allogene’s CEO

Follow BiotechTV

Sponsors

Sponsor Spotlight